In vitro screening and discovery, and in vivo PK & bioanalysis

Efficient, effective and robust screening for drug discovery and development

Focusing efforts on drug compounds that have the best chance of success delivers significant cost and time savings and ensures that safety and efficacy are integrated from the outset. Identifying the compounds to discard is nearly as important as choosing the ones to progress.

Our ADMET team provides complete absorption, distribution, metabolism, excretion and toxicity screening services to the most recent global recommended standards. Using the latest in vitro and in vivo assays, we provide rapid sample turnaround and high-quality data interpretation so that you can accelerate design cycles and make informed decisions about your drug discovery pipeline. 

As we explore novel active pharmaceutical ingredients (APIs) and extend development into previously unused formulations and formats, more challenging compound classes are being explored. Where high-throughput screening isn’t possible, we offer customized assay design that meets your needs, all carried out with complete confidence and confidentiality. 

Our assay services provide the complete package for drug compound characterization, including physicochemical properties, distribution, permeability, drug-drug interactions, metabolism and stability. Assay data helps our clients obtain an early view on the likely safety and efficacy of potential therapies and make informed decisions about formulation, drug delivery and manufacturing. 

An assay for every drug parameterv

We offer a comprehensive range of standardized assays that meet the latest global and regional regulatory standards. For more bespoke assays, contact our ADMET services team 

Physicochemical properties

Solubility 

Low solubility is a limiting factor for absorption and bioavailability. By identifying poorly soluble drug compounds early in the development process, developers can evaluate the resources and additional time needed to progress a therapy. 

By using the shake flask method, we determine kinetic and thermodynamic solubility, helping you to choose the most promising drug compounds to take through development in the most effective way. 

Learn more 

LogD 

LogD assays simulate the ability of chemicals to passively diffuse across biological membranes. Our assay uses the shake flask methodology and provides quantitative LogD7.4 values against a five-point standard curve.

Learn more

Chromatographic hydrophobicity index (CHI)

Using reverse-phase liquid chromatography (RP-LC) this assay uses physiochemical methods to determine hydrophobicity delivering an accurate CHILogD7.4 value.

Learn more

Chemical stability

This early-stage assay can determine the likely stability of drug compound by assessing its stability in buffer solutions. Hydrolysis, oxidation, light-catalyzed degradation and many other factors can be assessed with buffer solutions of varying temperature and pH. This can flag potential shelf-life issues as well as stability at the different pH’s which your drug product may encounter in vivo. Weak candidates can be removed from drug development pipelines before evaluation in vivo

Learn more

You may also like to take a look at our OECD 117 OECD 123 and OECD 107 methods which comprise part of our extensive array of regulatory physicochemical tests.

In vitro metabolism

Plasma stability 

Rapid metabolism lowers drug exposure at the therapeutic target. Furthermore unstable compounds can cause issues in in vitro plasma protein binding and in vivo pharmacokinetic studies as they continue to degrade after blood samples are taken. Plasma stability assays identify these compounds early in development as part of prodrug screening programs, providing an accurate measure of test compound degradation over time. 

Learn more

Microsome and S9 stability 

Most drugs are biotransformed within the body by metabolic enzymes; the rate of this metabolism determines how much of the drug is exposed to its target. Microsome assays help to determine the stability of drug compounds by assessing the effects of phase I enzymes. In addition, S9 assays can determine the impact of phase I and II enzymes in the cytosolic liver fraction and provide a cost-effective alternative to hepatocyte assays. 

Learn more

Hepatocyte stability 

Metabolic stability is directly correlated to both therapeutic toxicity and efficacy. By testing drug compounds in isolated, whole hepatocytes, the entire complement of drug-metabolizing enzymes can be assessed with phase I and II coordinated activity. Comparison of datasets across species contributes to predictions of drug exposure in humans. 

Learn more

CYP 450 inhibition 

This assay measures the inhibitory potency (IC50) of drug compounds against the five main drug-metabolizing enzymes: CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 

Learn more

We also provide an extended assay for the seven FDA-recommended drug-metabolizing enzymes which includes CYP2B6 and CYP2C8.

Learn more

CYP induction 

Metabolic drug-drug interactions following co-administration of xenobiotics are known to result in either increased toxicity or reduced efficacy. Understanding a drug's liability to induce Cytochrome P450 enzymes is required to guide drug development.

We offer qPCR (mRNA) analysis and enzyme activity profiles in primary hepatocytes from both human and animal species.

Time-dependent inhibition (TDI)

By measuring the amount of irreversible and quasi-irreversible CYP metabolism, the loss of enzyme function can be used to assess clinically relevant drug-drug interactions. TDI percentages are quantitatively calculated for each test compound against CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.

Learn more

In vitro permeability and transporters

Caco-2 permeability 

Using Caco-2, an immortal human colon carcinoma cell line, drug permeability can be assessed in an environment similar to the epithelial cells present in the small intestine. Apparent permeability (Papp) figures are calculated, measuring efflux and the activation of P-glycoprotein (P-gp), BCRP or MRP2 cell membrane transporters. 

Learn more

MDCK permeability 

Using a monolayer of canine kidney cell lines overexpressing human transporters, permeability and active transport can be assessed for drug compounds. By effectively mimicking the barrier between the intestinal lumen and blood supply from the hepatic portal vein, Papp is determined and compounds that are P-gp/BCRP substrates are identified.

Learn more

Protein binding

Plasma Protein binding 

When drugs bind to proteins within blood, plasma and tissues it reduces the drug free fraction that can permeate cell membranes and generate pharmacological effects.

Equilibrium dialysis is effective at determining protein binding affinities and the influence on dosing, efficacy, clearance rate and drug-drug interactions. 

Learn more

Blood plasma partitioning ratio 

In vivo analysis of drug concentration and pharmacokinetic properties are often determined in plasma, but these figures can be misleading if compounds have a high affinity for blood components, such as hemoglobin or cytosol binding proteins. By measuring concentration in the whole blood, we provide a blood plasma partitioning ratio, demonstrating red blood cell interactions and providing the complete picture of pharmacokinetic parameters in plasma.   

Learn more

Other metrics are available upon request.

Bioanalysis

Bioanalysis of in vivo samples

Drug formulation is critical to ensuring effective drug release, absorption and metabolism which, in turn, delivers the desired pharmacokinetic profile and pharmacodynamic response. 

Our bioanalysis assays quantify the test compound in in vivo samples from pharmacokinetic studies, enabling developers to check the suitability of the drug delivery mechanisms.

Learn more

Toxicity

ADMET screening for cytotoxicity

Using the HepG2 epithelial cell line, this assay measures cell viability in the presence of the test compound. Using fluorometric/colorimetric measures, we determine the cellular metabolic activity and mitochondrial viability of cells to give a viable cell count. 

Learn more

hERG inhibition

The large inner cavity of the human ether-a-go-go-related gene (hERG) potassium channel makes it particularly sensitive to drug binding. The inhibition of this channel, present in cardiac tissue, can lead to a loss of function and Long QT Syndrome (LQTS). With cardiovascular safety issues being the main reason for drug development candidate failure, this is an important assay early in the drug development process. Our assay provides concentration-response curves so that developers can be confident that inhibition lies within permissible levels. 

Learn more